Trials / Recruiting
RecruitingNCT05868928
Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis
Imaging Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis (IRRAS-BM)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 132 (estimated)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial uses multi-parametric magnetic resonance imaging (MRI) to develop and validate imaging risk score to predict radiation necrosis in participants with brain metastasis treated with radiation therapy. Diagnostic procedures, such as multi-parametric magnetic resonance imaging (MRI), may improve the ability to diagnose radiation necrosis early and help establish treatment strategies.
Detailed description
PRIMARY OBJECTIVE: I. To develop an imaging risk score for recurrence after stereotactic radiosurgery (SRS) in brain metastasis using multiparametric MRI. II. To validate the imaging risk score in retrospective external validation and prospective internal validation test set. SECONDARY OBJECTIVE: I. To predict radiation necrosis using imaging risk score. OUTLINE: Participants undergo multi-parametric MRI including 3D pre- and contrast-enhanced T1 weighted image, T2 weighted image, diffusion-weighted image, dynamic susceptibility contrast MRI, and arterial spin labeling image before receiving SRS, and every 3 months after SRS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Magnetic resonance imaging (MRI) | Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image |
| DIAGNOSTIC_TEST | Diffusion-weighted MRI | Diffusion-weighted MRI |
| DIAGNOSTIC_TEST | Arterial spin labeling (ASL) | Cerebral blood flow imaging parameter |
| DIAGNOSTIC_TEST | Dynamic susceptibility contrast-MRI (DSC-MRI) | Cerebral blood volume and vessel architectural imaging parameters |
Timeline
- Start date
- 2023-12-07
- Primary completion
- 2026-07-30
- Completion
- 2026-07-30
- First posted
- 2023-05-22
- Last updated
- 2024-05-14
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05868928. Inclusion in this directory is not an endorsement.